Newron Wins Long-Term EU Patent Protection for Lead Schizophrenia Drug Evenamide

Newron Pharmaceuticals SpA ( (CH:NWRN) ) has provided an update.

Newron Pharmaceuticals has secured a new European compound patent (EP4615820) covering the crystalline forms, manufacturing processes and uses of its lead product candidate Evenamide, with protection expected to run until 2044. The patent grant, which builds on an already comprehensive IP estate and is being pursued in major global markets, strengthens Newron’s exclusivity and underpins the therapeutic and commercial potential of Evenamide in treatment-resistant schizophrenia, reinforcing the company’s long-term positioning in CNS drug development and its strategy to capture value from a first-in-class mechanism in a large unmet-need segment of the schizophrenia market.

The most recent analyst rating on (CH:NWRN) stock is a Buy with a CHF26.00 price target. To see the full list of analyst forecasts on Newron Pharmaceuticals SpA stock, see the CH:NWRN Stock Forecast page.

More about Newron Pharmaceuticals SpA

Newron Pharmaceuticals is a biopharmaceutical company focused on developing novel therapies for diseases of the central and peripheral nervous system. Headquartered near Milan, it has advanced neuroscience-based drugs from discovery to market, including its first marketed product Xadago/Safinamide for Parkinson’s disease, which is approved across Europe, North America, Latin America, the Middle East and Asia through regional partners. Its lead pipeline asset, Evenamide, a novel glutamate modulator positioned as a potential first add-on therapy for treatment-resistant and poorly responsive schizophrenia, is in a global Phase III ENIGMA-TRS programme, supported by development and commercialisation deals in Japan, other Asian territories and South Korea.

Average Trading Volume: 144,820

Technical Sentiment Signal: Buy

Current Market Cap: CHF476.1M

See more insights into NWRN stock on TipRanks’ Stock Analysis page.